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1. Introduction 
Modern society with its bad ecology, chronic stress and the prevalence of mental activities 
over physical no longer treats pregnancy as a physiological state with "natural" course of 
events but the state that requires intensive medical supervision, active, even invasive, 
intervention during pregnancy and delivery. In most cases such intervention is the only way 
to save life for a mother and her child. Therefore, modern obstetrics is primarily a surgical 
one. With the overall growth of obstetric operations a number of radical interventions to 
remove the reproductive organ is also increasing .The main cause of hysterectomy and 
sometimes death of a patient in obstetric practice is massive obstetric hemorrhage (post-
partum haemorrhage - PPH). Life-threatening bleeding occurs in about 10% of deliveries 
worldwide (The Department of Health UK. Why mothers die. A report.., 2004). Obstetric 
hemorrhage is a major cause of maternal mortality, with 25 - 30% of overall death cases in 
prergnancy (Bonnar, 2000; Make Every Mather and Child count: the World Health Report.: 
WHO, 2005). The occurance of massive obstetric hemorrhage in developed and developing 
countries differs greatly (Ben HȎmid et al., 2006; Sheiner et al., 2005). The risk to die from 
obstetric hemorrhage in developed countries is 1:100 000, while in developing countries the 
rate reaches 1: 1000 births (Mousa & Alfirevic, 2003). According to WHO bleeding is among 
the "big five" of causes of maternal mortality that leads to an on-going research to find 
various methods to stop bleeding, as well as blood transfusion (Baudo et al., 2001). 
Cases with heavy bleeding, such as hysterorrhesis, premature detachment placenta increta 
and uterine atony require intensive resuscitation, and often result in hysterectomy. The 
problem of PPH treatment can be hardly overestimated in modern science and offers 
challenges to specialists in obstetrics, hematology and intensive care, in other words it 
requires inter-disciplinary approach to its solution.  
It is known that only 62 - 65 % of vaginal deliveries are accompanied by physiological 
hemorrhage, and one third of patients lose from 500 ml to 1000 ml of blood and in 3 - 8 % 
hemorrhage exceeds 1.5 % of body weight and is to be massive and requires infusion of 
erythrocytes and hysterectomy. Definitions of PPH vary and relate to the patients with 
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blood loss of 50 % of overall circulating blood within 3 hours, or hemorrhage > 150 
ml/minute. WHO defines PPH as a loss of blood in volume of 500 ml or more during or 
after delivery, or any quantity of blood loss after the delivery which leads to instability of 
blood circulation (World Health Organization [WHO], 2009). 
Most authors believe that uterine atony is the cause (75-90%) of early postpartum 
hemorrhage (Henrich et al., 2008; Ramanathan & Arulkumaran, 2006; Reynders et al., 2006). 
In this condition, uterus loses its ability to involution and does not react to medications and 
other types of stimulation (Roeal College of Obstetricians and Gynaecologists UK. 
Prevention .., 2009). Disorders of functional state of myometrium are possible due to 
prolonged labor, due to the of use of medication, reducing uterine tonus, due to greater 
amount of oxytocin in labor (Grotegut et al., 2011). Obstetric haemorrhage is characterized 
by suddenness and high temper of blood loss. Besides, reduced adaptive abilities of mother 
organism upon giving birth, her somatic diseases and pathology in pregnancy easily 
contribute to the rapid development of coagulopathy, to the shock phenomenon and 
multiple organ failure (Macphail & Talks, 2004). An increased number of caesarean section 
worldwide is one of the factors that cause the growth of postpartum haemorrhage 
(Deneux_Tharaux et al., 2006; Murkin, 2009). According to Ohkuchi et al. (2003), an average 
blood loss during vaginal delivery was 615 ml, whereas in cesarean section – 1530 ml. 
Standard methods of treatment of massive PPH include therapeutic (hemotransfusion 
therapy and uterotonics) and surgical methods of hemorrhage control (Bouwmeester et al., 
2005; Macphail & Talks, 2004; Mousa & Alfirevic, 2007). First aid in obstetric hemorrhage in 
most countries traditionally employs the use of uterotonics and prostaglandins, manual 
examination of uterus and birth canals and uterine massage (Abdel-Aleem et al., 2010; 
Henrich et al., 2008; Price & Lynch, 2005). If uterotonics and manual examination of the 
uterus prove to be ineffective, more complex surgical technics are traditionally employed - 
uterine artery ligation, internal iliac artery ligation and hysterectomy. 
Many publications and reviews that relate to the problem of obstetric bleeding offer the 
opportunity and place to discuss new methods to stop postpartum bleeding. In recent years, 
a series of invasive manipulations is used as a rather effective measure to stop postpartum 
bleeding, for example - uterine balloon tamponade (Bakri et al., 2001; Dabelea et al., 2007; 
Penninx et al., 2010), uterine devascularization and compression sutures (Allam & B-Lynch, 
2005; Sentilhes et al., 2008a; Sentilhes et al., 2008b), uterine artery embolization (Chauleur et 
al., 2008; Irion et al., 2008; Vedantham et al., 1997), internal iliac artery and uterine artery 
ligation (Api et al., 2005; O'Leary, 1995; Papp et al., 2006), that, to some extent, is an 
alternative to traditional hysterectomy (El-Hamamy & B-Lynch, 2005; Malibary, 2004; Smith 
& Baskett, 2003). 
In the , in a majority of obstetric hospitals hysterectomy still plays a crucial role in the 
algorithm of surgical treatment of massive obstetric hemorrhage, and causes women to 
become infertile. 
In accordance with nowadays approaches, to save a woman’s life as well as her 
reproductive function in the course of solving the problem of bleedings upon pregnancy, 
delivery and early postpartum period is a priority. In this regard, research efforts for 
additional, effective methods of PPH management alternative to hysterectomy, is very 
important. 
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Recently advances for stopping PPH and decreasing the need in donor blood become crucial 
in the field of pharmacological correction of hemostasis as well. In particular, empirical use 
of recombinant factor VIIa (rFVIIa) is studied in the treatment of obstetric hemorrhage 
refractory to conventional conservative therapy.  
2. Indications and clinical situations for rFVIIa administration 
Originally rFVIIȎ (NovoSeven®; Novo Nordisk A/S, Bagsvaerd, Denmark) has been 
developed for treatment of spontaneous and/or surgical bleeding in patients, suffering from 
haemophilia A or B with formation of autoantibodies to FVIII or FIX as a result of 
compensation of their deficiency in the course of replacement therapy (Abshire & Kenet, 
2004; Lusher et al., 1998; Negrier & Hay, 2000; Shapiro et al., 1998; Sobieszczyk & 
Breborowicz, 2006). Now rFVIIȎ is licensed for the use in a number of countries. In 1999 
Food and Drug Administration (FDA), United States of America approved rFVIIa for 
treatment of hemophilia A or B in patients with inhibitors to FVIII or FIX. Further, in 2005, 
FDA also approved the use of rFVIIȎ in patients with congenital deficiency of factor VII 
(K.A. O’Connell et al., 2006). In Europe rFVIIȎ is also prescribed to stop bleeding in patients 
with acquired hemophilia and Glanzmann thrombasthenia (Franchini et al., 2005a; Hedner 
& Erhardtsen, 2002; Jurlander et al., 2001; Kessler, 2000). 
Except above listed indications, any use of rFVIIa is reviewed «off-label» and responsibility 
for its decision remains for the attending physician. For the last decade, the use of rFVIIa, 
with more specified data about mechanisms of its action has been successfully approved 
«off-label» to stop other uncontrolled hemorrhages unassociated with haemophilia, to 
reduce the need for allogenic blood. They included intracranial hemorrhage, bleedings due 
to coumarin use, hepatic coagulopathy, major surgery and traumas (Aggarwal et al., 2004; 
Aldouri, 2002; Dutton al., 2004; Eikelboom et al., 2003; Franchini et al., 2007; Ghorashian & 
Hunt, 2004; Hedner, 2003; Mathew, 2004; Martinowitz et al., 2002; Martinowitz & 
Michaelson, 2005; Mayo et al., 2004; Mittal & Watson, 2006; O’Connell et al., 2003; Price et 
al., 2004; Roberts et al., 2004; Sobieszczyk & Breborowicz, 2004; Uhlmann & Eby, 2004; 
Vincent et al., 2006). 
3. World experience of use of rFVIIa in treatment of PPH 
The first experience of successful treatment of intractable obstetric bleeding in 
nonhaemophilic patients with rFVIIa was published by Moscardo et al. in 2001 (Moscardo et 
al., 2001), who reported that rFVIIa showed high hemostatic effect in life-threatening PPH 
after caesarean section in women with disseminated intravascular coagulation (DIC) 
syndrome, impaired liver and kidney failure. Later, Breborowicz et al. (2002) reported the 
results of the experience of PPH treatment when rFVIIa application helped to avoid 
hysterectomy in two of six cases. 
Hossain et al. (2007) described the results of cohort retrospective study of 34 patients with 
blood loss more than 1500 ml, 18 of them received rFVIIa treatment. Ahonen et al. (2007) 
compared results of 26 women receiving rFVIIa with 22 women of control group, with PPH 
without rFVIIa. In both studies the causes of PPH were: uterine hypotension, abnormal 
placentation, premature placental detachment, as well as hysterorrhesis or vaginal 
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laceration were. Before rFVIIa administration women received oxitocics, uterus massage, 
uterine artery ligation and, in some cases, hysterectomy. 
Above-mentioned and other reports were very important, as treatment of life-threatening 
PPH still remains acute problem. Moreover it can demand hysterectomy with subsequent 
loss of reproductive function of woman, despite the fact that rendered aid was not included 
in the number of registered indications for this clinical situation (Franchini et al., 2007).  
Presently there is a number of works available for successful empirical rFVIIa application in 
treatment of massive PPH, with introduced refractory to conservative methods of treatment. 
(Aggarwal et al., 2004; Ahonen & Jokela, 2005; Ahonen et al., 2007; Boehlen et al., 2004; 
Bomken et al., 2009; Bouwmeester et al., 2003; Boyer-Neumann et al., 2003; Breborowicz et 
al., 2002; Brueckner et. al., 2001; Dart et al., 2004; Dutton et al., 2004; Eikelboom et al., 2003; 
Franchini et al., 2007; Franchini et al., 2008; Hollnberger et al., 2005; Holub et al., 2005; 
Jansen et al., 2005; Jimenez-Yuste et al., 2000; Kale et al., 2004; Kretzschmar et al., 2003; 
Macphail et al., 2004; Martinowitz & Michaelson, 2005; Mayo et al., 2004; Merchant et al., 
2004; Mittal & Watson, 2006; Moscardo et al., 2001; Mousa & Walkinshaw, 2001; Mousa & 
Alfirevic, 2003,2007; Nowacka et al., 2005; Palomino et al., 2006; Pepas et al., 2006; Price et 
al., 2004; Segal et al., 2004; Shamsi et al., 2005; Shander et al., 2005; Sobieszczyk et al., 2002, 
2004, 2006; Sokolic et al., 2002; Tanchev et al., 2005; Verre et al., 2006; Vincent et al., 2006; 
Welsh et al., 2008; Zupancic et al., 2002). 
There is also data about rFVIIa efficacy in hemorrhage prevention during delivery in pregnant 
women with acquired impaired coagulation. (Eskandari et al., 2002; O’Connell et al., 2006). 
In Russia the first successful experience in this field took place in 2002 in Clinic of Professor 
Zinovij Barkagan (Russian Academy of Medical Sciences, Hematological Research Center, 
Altai department). The patient with severe postpartum hemorrhage and syndrome of 
massive hemotransfusions underwent a successful treatment and the followed long-term 
observations led to this publication. 
Nevertheless, there is not enough evidence in favor of rFVIIa application in postpartum 
hemorrhage. According to the last recommendations of World Health Organization the use 
of rFVIIa should be limited to primary defect symptoms of hemostasis. (World Health 
Organization [WHO], 2009). The document also indicates that rFVIIa was given a priority 
interest to treat postpartum haemorrhage, mainly in industrialized developed countries due 
to its high cost. The broad use of rFVIIa is limited to the evidence in this area reporting that 
the use of rFVIIa is risky and even life-threatening . Despite the positive recommendations 
(Ahonen et al., 2007; Welsh et al., 2008) the practice of rFVIIa use in PPH is far from 
homogeneous (Haynes et al., 2007). Though it’s available to be prescribed, experts need to 
determine its effectiveness, safety in obstetric hemorrhage and dosage recommendations. It 
is also clear that further accumulation and generalization of rFVIIa administration in 
obstetric practice may serve as the basis to register indications for its possible prescription in 
obstetrics. 
4. Mechanism of hemostatic action of rFVIIa 
FVII of natural origin, as well as a recombinant product, plays a key role in the haemostatic 
reactions in a human body. According to the cellular model of coagulation (Hoffman, 2003.) 
www.intechopen.com
 
Pharmacotherapy of Massive Obstetric Bleedings as Alternative to Hysterectomy 
 
201 
after injury of vascular walls tissue factor (TF) gets into circulating blood to form a complex 
TF-FVII on the surface of cells containing TF. Complexes of TF-FVII activate factor X, which, 
in its turn, promotes the transformation of prothrombin to thrombin. A limited amount of 
formed thrombin activates cofactors V, VIII and XI, as well as platelets accumulated at the 
site of injury. Activated platelets secrete negatively charged phospholipids 
(phosphatidylserine) on membrane surface, and FIXa, FVIIIa and FXIa bound to their 
surface, which leads to further activation of FX and a massive thrombin formation (Monroe 
et al., 1997). The formation of large doses of thrombin leads to thrombin-activated 
fibrinolysis inhibitor (TAFI), which protects the fibrin clot from early dissolution (Bajzar et 
al., 1995). Direct activation of FX on the surface of activated platelets in the absence of TF, 
which leads to increased thrombin formation, may explain the mechanism of action of 
rFVIIa in the local cases of acquired coagulopathy due to trauma or surgery (Gabriel et al., 
2004; Hedner, 2001; Hoffman et al., 1998; Lisman & De Groot, 2003; Monroe et al., 1997). 
5. Original researches 
Our research project offers a comparative assessment of rFVIIa effectiveness against 
(NovoSeven ®; Novo Nordisk A / S, Bagsvaerd, Denmark) PPH, due to the cause of 
bleeding, blood loss, dynamics of hemostatic disorders and period of drug administration 
from the start of bleeding. That is the main objective of the research. 
In this study we obtained data on 75 patients with PPH in study conducted within the scope 
of prospective analysis, and 30 patients with PPH for the retrospective analysis. Recruitment 
campaign in patients was carried out randomly in accordance with internationally 
recognized protocol in major obstetric clinics in Russian cities - Barnaul, Krasnoyarsk, 
Bryansk, and Syktyvkar. The criterion for selection of patients for the research was the same 
pathology - a massive haemorrhage (PPH), which started during pregnancy, delivery and in 
the postpartum period. By “massive” we understand the blood loss that constitutes more 
than 1.5% of patient body weight or less, leading to hemodynamic disturbances. 
The age range of women participating in this study varied: from 18 to 44, and average age 
was 28,6 ± 6,3 years. Gestational age at the time of bleeding was also different - from 24 to 43 
weeks, average gestational age at delivery was 35,5 ± 5,5 weeks, that is, in the majority of 
patients (63.8%) bleeding occurred at full-term pregnancy. 
Pregnancy which resulted in spontaneous vaginal birth is found only in 46 women (43.8%), 
the greater part of pregnant women (56.2%) required surgical delivery by cesarean section 
(93.2% women), or the use of obstetric forceps (6,8%). In more than half of the observations 
(56.2%) major bleeding occurred in the postpartum period, approximately in every fourth - 
during pregnancy (26.7%), almost in every sixth - during delivery (17.1%). 
According to the study, all patients were divided into two groups – study group and control 
group (see pic. 1). The main principle of this division was the use of rFVIIa along with 
traditional therapy consisting of pharmacologic hemostasis in life-threatening obstetric 
hemorrhage in 75 patients (study group). rFVIIa was given intravenously at doses ranging 
from 13,6 to 146,5 mg / kg body weight, an average dose of rFVIIa was 65,4 ± 36,7 mg / kg. 
Criteria for enrollment in the study group are: reproductive age 18 - 44 years, the presence 
of massive obstetric haemorrhage, rFVIIa administration to correct hemostasis. Negative 
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factor for enrollment: physiological blood loss during delivery or in the postpartum period, 
the presence of massive obstetric haemorrhage without rFVIIa administration to correct 
hemostasis. The rFVIIa was used as a supplement to the traditional scheme against PPH. 
The control group retrospectively consisted of 30 patients with PPH, and their treatment 
was delivered according to classical method, which includes the use of drugs that reduce 
uterus size, uterine massage, manual examination of the uterine cavity, infusion and 
transfusion therapy with fresh frozen plasma, blood cells - red blood cells and platelets, 
protease inhibitors, as well as surgical methods of hemostasis, which is consistent with the 
recommendations of several experts (Ahonen et al., 2010; Franchini et al., 2007; La Belle 
& Kitchens, 2007; Phillips et al., 2009; Shander et al., 2005; Sobieszczyk & Breborowicz, 
2006a; Vincent et al., 2006; Welsh et al., 2008). 
 
Pic. 1. The division of women with PPH into groups / subgroups in the study 
The factors for the analysis in the study group: age of patients in the target group, 
gestational age at the time of massive bleeding, the methods of delivery, as well as obstetric 
data, reproductive and physical history, which in most patients characterized by the 
presence of several diseases in their reproductive system, abnormal cardiac and vascular 
system, presence of chronic infections, viral and toxic liver injury. 
Analysis of the characteristics of hemorrhagic syndrome showed similar results in two 
groups compared to hemorrhage causes, the volume of blood loss, hemoglobin levels and 
bleeding tempo and other similar factors.  
By the clinical manifestations of PPH we divided study group into two subgroups for 
further in-depth analysis. The first subgroup included 47 women with the classical picture 
of obstetric haemorrhage. rFVIIa was administered to stop PPH prior to the use of traumatic 
surgical methods of treatment. The purpose of rFVIIa administration in patients of this 
subgroup was to stop local uterine bleeding without a laparotomy and to preserve the 
uterus. 
 
Pregnant women with PPH (n=105) 
Тherapy with rFVIIa, 
Stady group (n=75) 
Therapy withaut rFVIIa, 
Control group (n=30) 
Local (uterine) bleeding, 
subgroup 1 (n=47) 
Systemic bleeding, 
characteristic of DIC, subgroup 2 (n=28) 
Without organ dysfunktion, 
subgroup 2А (n=17) 
With organ dysfunction, 
subgroup 2В (n=11) 
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The second group which included 28 patients with obstetric DIC with massive blood loss, 
according to the criteria,offered by LaBelle & Kitchens (2007). Prior to the introduction of 
rFVIIa in this group, the classical scheme has been implemented in full, using the known 
methods of surgery, even a hysterectomy in 16 patients (57.1%). At the same time patients 
with DIC had systemic bleeding (hematoma under the skin, bleeding from the injection site, 
gastrointestinal bleeding, hematuria, and others in a variety of combinations), which 
threatened their lives. Thus, we introduced a special subgroup – 2B, which consisted of 11 
patients in whom PPH was complicated with organ dysfunction. 
To assess the effectiveness of rFVIIa in treatment PPH we indicated negative factors - early 
and late. Early negative factors are as follows: 
- volume of blood loss ≥ 2.200 ml; 
- rate of blood loss> 30 ml / min; 
- hemoglobin level ≤ 60 g / l; 
- period of time from the beginning of bleeding to rFVIIa administration > 120 min in the 
study group (the comparison group - the time from the beginning of bleeding to its 
termination); 
Late negative factors -total hysterectomy and death of both mother and fetus. 
In patients with PPH, with general clinical examination and measurement of parameters of 
blood loss, an analysis of core indicators of hemostasis was performed (Practical hemostasis 
and thrombosis, 2005). The number of platelets in blood, measurement of activated partial 
thromboplastin time (APTT), prothrombin time (PT) and fibrinogen concentrations 
according to Clauss were subject to the analysis.Moreover, the activity of antithrombin in 
plasma was evaluated by amidolytic method. Laboratory studies were conducted prior to 
bleeding, during (prior to use rFVIIa), and after 1-5 hours, 24 hours and 2-5 days after rFVII 
administration. 
5.1 Statistical analysis 
The results were statistically computed in Excel software by methods of calculations of 
indicators in descriptive statistics. Data analysis in small groups during the distribution was 
carried out by methods of nonparametric statistics, using Fisher angular transducer, 
criterion χ2 with Bonferroni correction, as well as T-score according to Wilcoxon (Wilcoxon 
F. et al., 1963). Assessment of the efficacy of rFVIIa for treatment of PPH was conducted 
according to the generally accepted criteria in evidence-based medicine, such as Absolute 
risk reduction (ARR), Relative risk (Rr), Relative Risk Reduction (RRR), Number needed to 
treat (NNT), Confidence interval (CI). 
5.2 Study results  
Upon the analysis of pregnancy complications in patients in the compared groups we 
obtained interesting results (Table 1). Complicated course of pregnancy due to the taken 
nosology was characteristic in patients with obstetrical DIC and organ dysfunction rather 
than in patients with uterine bleeding. Thus, systemic bleeding in the setting of massive 
obstetric blood loss (subgroup 2A) was more frequent than in patients with local 
hemorrhage (subgroup 1) and antenatal fetal death.  
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Pathology form 
Study group (n=75) 
Р value Subgroup 1 
(n=47) 
Subgroup 2 (n=28) 
Subgroup 
2А(n=17) 
Subgroup 
2В(n=11) 
abs. % abs. % abs. % 
Pathologic placentation 7 14,89 4 23,53 1 9,09 
≥0,05 
≥0,05 
≥0,05 
Uterine scar 8 17,02 3 17,65 3 27,27 
≥0,05 
≥0,05 
≥0,05 
Premature detachment 
of physiological 
placenta 
7 14,89 3 17,65 3 27,27 
≥0,05 
≥0,05 
≥0,05 
Preeclampsia 2 4,26 1 5,88 4 36,36 
Р1-2В = 
0,001 
Intrauterine growth 
retardation 
syndrome 
5 10,64 1 5,88 3 27,27 Р≥ 0,05 
Fetus prenatal infection 14 29,79 8 47,06 8 72,73 
Р1-2В = 
0,008 
Antenatal fetal death 7 14,89 2 11,76 6 54,55 
Р1-2В = 
0,004 
Р 2А-2В = 
0,01 
Total number of women 
with pregnancy 
complications 
30 63,83 15 88,24 11 100,00 
Р1-2В = 
0,01 
Table 1. Complications of pregnancy in women with pharmacological correction of 
hemostasis by rFVIIa 
In a particularly severe clinical cases, namely in patients with severe DIC syndrome and the 
presence of multiple organ failure (subgroup 2B), the frequency of such pathological 
conditions like preeclampsia, intrauterine infection and antenatal fetal death as a 
consequence of placental dysfunction occurred more frequently than in the two other 
subgroups.  
With regard to today's medical science and the latest scientific advances, it is likely that the 
high incidence of gestational complications such as preeclampsia, placental insufficiency 
with antenatal fetal death, are often caused by and associated with severe disorders of 
hemostasis, hereditary and acquired thrombophilia. High frequency of these complications 
in the subgroup of patients with massive blood loss, obstetrical DIC and organ dysfunction 
is consistent with the abovementioned.  
Pregnancy pathologies partly determined the character of complications during delivery 
and the postpartum period, which caused the development of PPH (Table 2). 
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Pathology form 
Study group (n=75) 
Subgroup 1 (n=47) Subgroup 2 (n=28) 
abs. % abs. % Р value 
Uterine atony 17 36,17 6 21,43 0,08 
Pathologic placentation 6 12,77 1 3,57 0,072 
Premature detachment of 
physiological placenta 
7 14,89 6 21,43 0,1 
Coagulopathy caused by 
somatic diseases 
3 6,38 2 7,14 0,1 
Coagulopathy caused by 
pregnancy complications 
7 14,89 1 3,57 0,045 
Retained placenta 6 12,77 5 17,85 0,1 
Obstetric trauma 1 2,13 4 14,30 0,022 
Amniotic fluid embolism 0 0,00 2 7,14 - 
Obstetric sepsis 0 0,00 1 3,57 - 
Table 2. Causes of massive obstetric hemorrhage in women with pharmacological correction 
of hemostasis 
Analysis of the characteristics of a hemorrhagic syndrome in the study group showed 
significant differences in subgroups (Table 3). Thus, the total volume of blood loss and 
blood loss before the drug administration in subgroup with local (uterine) bleeding were 
significantly lower than in subgroup 2 with the development of DIC. 
Criteria of comparison 
Study group (n=75) 
Р value Subgroup 1 
(n=47) 
Subgroup 2 
(n=28) 
Х ± m Х ± m 
Volume of blood loss prior to rFVIIȎ 
administration, ml 
1368,09 ± 77,14 2230,82 ± 198,20 0,01 
Total volume of blood loss, ml 1740,21 ± 114,45 2605,16 ± 402,68 0,01 
Blood loss rate, ml/min 30,89 ± 3,97 29,91 ± 7,81 0,1 
Haemoglobin level at the moment 
of rFVIIa administration, g/L 
71,48 ± 2,73 56,28 ± 4,07 0,05 
Time from beginning of 
hemorrhage to rFVIIȎ 
administration, min 
119,47 ± 22,82 318,02 ± 26,6 0,001 
rFVIIȎ dose, mkg/kg 55,47 ± 4,24 70,37 ±-4,77 0,05 
Repeated rFVIIȎ administration, 
number of cases 
11 23,40% 8 28,55% 0,01 
Volume of blood loss after rFVIIȎ 
administration, ml 
340,21 ± 62,28 688,77 ± 88,80 0,001 
Table 3. Indicators of blood loss and characteristics of the use of rFVIIa in patients with PPH 
in the study group 
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Time from the beginning of bleeding to rFVIIa administration was significantly higher 
among patients with obstetric DIC (subgroup 2). Obviously this is due to the fact that rFVIIa 
is considered by obstetricians and emergency physicians as a backup means to stop PPH 
after using known hemostatic technologies, including hysterectomy. However, one should 
pay attention to the fact that the dosage of rFVIIa in patients with DIC and pattern of 
administration were higher in patients with local (uterine) bleeding (subgroup 1). Despite 
this fact, PPH in subgroup 2 continued the use of rFVIIa, and estimated blood loss was 
higher compared to subgroup 1.  
Effectiveness of rFVIIa in treatment PPH was assessed according to the prior given criteria 
of negative factors. The absolute number of early negative factors in the compared groups / 
subgroups is presented in Table 4.  
Criteria of negative factors 
Study group (n=75) 
Control 
group 
(n=30) 
Subgroup 1 
(n=47) 
Subgroup 2(n=28) 
Subgroup 
2А (n=17) 
Subgroup 
2В (n=11) Total 
abs. abs. abs. abs. abs. 
Volume of blood loss 
≥2.200 ml 2 8 3 11 5 
Blood loss rate >30 
mL/min 
15 5 1 6 4 
Haemoglobin level in 
blood ≤ 60 g/L 13 8 8 16 15 
Time from beginning of 
hemorrhage to  
rFVIIȎ 
administration > 120 min 
10 6 7 13 19 
Volume of blood loss after 
rFVIIȎ administration, 
>300 ml 
14 10 7 17 2 
Table 4. Early negative factors in women with PPH, depending on the use of rFVIIa in the 
therapy 
Estimate of efficiency according to the blood loss criterion in patients of subgroup 1 (with 
local uterine bleeding) showed a relative risk reduction by 75%, according to the criterion of 
depth of anemia – by 45% and with the early administration of the preparation (less than 
120 minutes since the beginning of bleeding) – by 66%, indicating a high clinical efficacy of 
rFVIIa in treatment of PPH not complicated by DIC (Table 5). To avoid adverse outcomes on 
all reflected criteria from 4, 5 to 7, 8 patients are needed to be treated in this group. 
In contrast, in women with systemic bleeding due to underlying DIC (subgroup 2) absolute 
risk reduction was negative (Table 6). This suggests that the incidence of negative factors in 
the study group is higher than in the control group. The reduction of relative risk in patients 
of subgroup 2 accounted for 26%, suggesting that there is clinical effect from the use of 
rFVIIa, especially with the early introduction of preparation (≤ 120 min). 
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Factors ARR NNT Rr RRR CI (95%) 
Volume of blood loss  
≥2.200 ml 0,128 7,8 0,25 75% 
0,274; 
0,018 
Blood loss rate  
>30 mL/min 
-0,189 -5,3 2,45 -1,45 
-0,043; -
0,335 
Haemoglobin level in blood  
≤ 60 g/L 0,224 4,5 0,55 45% 
0,370; 
0,078 
Time from beginning  
of hemorrhage to  
rFVIIȎ administration  
>120 min 
-0,418 -2,4 0,34 66% 
0,272; 
0,564 
Table 5. The effectiveness of rFVIIa administration in patients with local uterine bleeding 
(subgroup 1)  
Factors ARR NNT Rr RRR CI (95%) 
Volume of blood loss  
≥2.200 ml -0,222 -4,5 2,31 -1,31 
-0,028; -
0,416 
Blood loss rate 
>30 mL/min 
-0,084 -11,9 1,65 -65% 0,110; 0,278 
Haemoglobin level in blood  
≤ 60 g/L -0,071 -14,1 1,14 -14% 0,123; 0,265 
Time from beginning  
of hemorrhage to  
rFVIIȎ administration  
>120 min 
-0,166 -6,0 0,74 26% 0,028; 0,360 
Table 6. The effectiveness of rFVIIa administration in patients with PPH in the setting of DIC 
(subgroup 2) 
This fact has motivated us to carry on more detailed analysis of the effectiveness of 
preparation in subgroups of women with DIC (Table 7). 
The effectiveness of rFVIIa in systemic bleeding with simultaneous presence of organ 
dysfunction (in subgroup 2B) in prevention of large volume of blood loss was uncertain. 
According to the criterion of blood loss rate we obtained positive values of ARR, NNT, and 
RRR index was 31% in these patients, which corresponds to a positive clinical effect of rVIIa 
application in the "fast" bleeding. However, to prevent one negative factor in these cases 25 
patients should be treated. At the same time, in systemic bleeding without development of 
organ dysfunction (subgroup 2A) with early introduction of rFVIIa clinical efficacy was 
even greater (RRR = 44%). 
Thus, according to the results of this analysis we can conclude that the clinical efficacy of 
rFVIIa in treatment of PPH is the highest in patients with local (uterine) bleeding and only 
according to the selected criteria with the early rFVIIa administration in patients with the 
development of obstetrical DIC. 
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Factors 
ARR 
(2А) 
ARR 
(2B) 
NNT 
(2А) 
NNT 
(2 B) 
Rr 
(2A) 
Rr 
(2B) 
RRR 
(2A) 
RRR 
(2B) 
CI 
(95%) 
(2A) 
CI 
(95%) 
(2B) 
Volume of  
blood loss  
≥2.200 ml 
-0,3 -0,1 -3,30 -10,0 2,76 1,59 -1,76 -59% 
0,028; 
0,416 
-0,085; 
-0,285 
Blood loss rate 
 >30 mL/min 
-
0,164 
0,04 -6,1 25,0 2,26 0,69 
-
126% 
31% 
0,032; 
-0,36 
0,225; 
-0,145 
Haemoglobin  
level in blood 
≤ 60 g/L 
0,03 -0,22 33,3 -4,5 0,94 1,44 6% -44% 
0,226; 
-0,166 
-0,035; 
0,405 
Time from 
beginning of 
hemorrhage to 
rFVIIȎ 
administration 
>120 min  
-
0,278 
0,006 -3,6 166,7 0,56 1,01 44% -1% 
-0,082; 
-0,474 
0,191; 
-0,179 
Table 7. The effectiveness of rFVIIa administration in women with PPH, complicated by 
obstetrical DIC (subgroup 2A and 2B) 
We also took into account the absolute number of late adverse outcomes in compared 
groups/subgroups that are shown in Table 8. 
Criteria of negative factors 
Groups / subgroups of patients 
1 
(n=47) 
2A 
(n=17) 
2В 
(n=11) 
2 
(n=28) 
Control group 
(n=30) 
abs. abs. abs. abs. abs. 
Maternal mortality 0 0 6 6 2 
Perinatal mortality 4 7 3 10 3 
Total hysterectomy 9 8 12 20 19 
Table 8. Late adverse outcomes in the groups / subgroups of women with PPH 
Below, we provide separate analysis for each criterion, except for the maternal mortality, as 
it was not registered in subgroup 1. 
We did not obtain any data about the effect of rFVIIa administration in treatment of PPH on 
frequency of perinatal mortality in study groups (Table 9). 
Absolute risk reduction for this criterion was indicated in women with DIC, but relative risk 
reduction was not indicated, so it is obvious that administration of rFVIIa has no significant 
effect on fetal loss. In contrast, we obtained positive clinical results for the total 
hysterectomy criterion, although somewhat different in the subgroups of study group 
(Table 10).  
It is quite understandable that women with a local (uterine) bleeding according to the total 
hysterectomy criterion had negative rate of absolute risk reduction. This suggests that in  
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Values 
Local (uterine) 
bleeding 
(subgroup 1) 
Obstetric DIC, in 
general 
(subgroup 2) 
Systemic 
bleeding 
without organ 
dysfunction 
(subgroup 2А) 
Systemic 
bleeding  
with organ 
dysfunction 
(subgroup 2В) 
ARR -0,01 0,26 0,08 0,54 
NNT -67,1 3,9 13,1 1,9 
Rr 0,85 3,57 1,76 6,36 
RRR (%) 15 -2,57 -76 -5,36 
CI 95% (+) -0,030 0,514 0,153 1,073 
CI 95% (-) -0,104 0,131 -0,013 0,368 
Table 9. The effectiveness of rFVIIa administration in women with PPH, according to the 
criterion of perinatal mortality 
control group hysterectomy was performed much more frequently in order to stop bleeding 
than in the group with local (uterine) bleeding. Indicator for relative risk reduction in patients 
with massive local (uterine) bleeding recommended rFVIIa in their therapy was 70%, which 
was consistent with clinical effect to preserve healthy reproductive function. When we studied 
each case of hysterectomy in patients with local (uterine) bleeding (9 cases, or 19.1%) 
separately we found out that the use of rFVIIa was not effective in patients who had bleeding 
caused by pathologic placentation (placenta increta in 5 cases out of 9) and the development of 
Kuveler's uterus (4 cases out of 9) due to premature detachment of placenta. 
Values 
Local (uterine) 
bleeding 
(subgroup 1) 
Obstetric DIC, 
in general 
(subgroup 2) 
Systemic bleeding 
without organ 
dysfunction 
(subgroup 2А) 
Systemic 
bleeding  
with organ 
dysfunction 
(subgroup 2В) 
ARR -0,44 0,08 0,09 0,07 
NNT -2,3 12,4 10,6 13,8 
Rr 0,30 1,13 1,15 1,11 
RRR (%) 70 -13 -15 -11 
CI 95% (+) -0,884 0,162 0,188 0,145 
CI 95% (-) -0,531 -0,045 -0,074 -0,017 
Table 10. The effectiveness of rFVIIa administration in women with PPH, according to the 
total hysterectomy criterion 
Further, we compared clinical manifestations of PPH to effects of rFVIIa in women under 
study who have abnormal changes in hemostatic system, and the research data gives the 
foundation for the formation of hemorrhagic syndrome, and to assess the effectiveness and 
safety of pharmacological correction of bleeding. 
Based on coagulation results almost all patients (subgroups 1, 2) had the relative 
hypofibrinogenemia and hypocoagulation a few days prior to developing PPH (compared 
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to the physiological norm for this gestational age) (Tables 11-13). We can assume that these 
changes can reduce the so-called physiological hypercoagulability in pregnancy and may 
serve as the pathological basis for the formation of severe hemorrhagic syndrome during 
delivery. 
The manifestation of PPH was associated with thrombocytopenia, hypocoagulation on PT 
and dynamic lowering of fibrinogen concentrations. Later, the first hours after infusion of 
rFVIIa the termination or reduction of bleeding (see Table 11-13) was followed by 
depression of thrombocytopenia and hypofibrinogenemia which is to be the natural course, 
as the platelets and fibrinogen are the basis of a blood clot. 
Haemostatic 
markers  
The 
indicator 
for normal 
pregnancy 
in III 
trimester  
In patients  
1-7 days  
prior to 
administratio
n of rFVIIȎ 
During 
bleeding 
After rFVIIȎ administration 
In 30 
min 
In 1 – 5 
hours 
In 24 
hours 
In 2-5 
days 
Platelets, 
x109/l 
146-429 194,7±10,37 
177,6± 
8,2 
109± 
4,2 
114± 
7,9 
146± 
9,48 
161± 
5,8 
PT, ratio 0,87 0,96 1,16 1,02 0,87 1,05 0,94 
APPT, ratio 0,91 0,97 0,93 0,96 1,07 1,00 0,90 
Fibrinogen, 
g/l 
3,7-6,2 
3,42± 
0,16 
2,15± 
0,14 
2,09± 
0,13 
2,02± 
0,01 
2,55± 
0,12 
3,09± 
0,17 
Аntithrombin, 
% 
82 - 116 
93± 
4,4 
86± 
3,5 
87± 
4,8 
67,67± 
1,8 
91,38± 
1,59 
89,56± 
2,9 
Table 11. The dynamics of hemostasis in women of subgroup 1 (with local bleeding and 
uterine hypotension) before and after application of rFVIIa (X ± m); * - according to Abbassi-
Ghanavati et al. (2009). 
These shifts in patients of subgroup 1 were defined on the basis of shortening of PT and 
noticeable reduction of antithrombin activity. This indicates systemic, caused by rFVIIa 
interference increase of procoagulant properties of blood, along with moderate reduction of 
its anticoagulant potential, leading to clinically diagnosed hemostasis. Later, after 24 hours 
and more extended period of time , all abnormal changes appeared to be decreasing. 
Haemostatic study of the second subgroup in women with obstetric DIC, showed direct (see 
the results for subgroup 1 given above), but more deep disorders of studied 
hemocoagulation markers in the period preceding and during PPH (Tables 12). 
To determine the intensity, focus and accuracy of changes in hemostatic system in women 
after rFVIIa administration, we used a T-Wilcoxon test (Wilcoxon F, et al 1963). We analyzed 
changes in the pattern of bleeding, after 1-5 hours and 24 hours after the injection. The 
results were the following: the intensity of positive shift (in the direction of normal 
hemostasis) significantly prevails over the intensity of negative shift according to the 
following parameters: in patients with local uterine bleeding - protrombin time (P = 0.01), 24 
hours after the administration, number of platelets (P = 0.05) 24 hours after the 
administration; level of fibrinogen (P = 0.05), 24 hours after the administration, in patients 
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with DIC reliable shift only in number of platelets (P = 0.05) 24 hours after the 
administration . For all other parameters changes are not significant, and in patients with 
DIC there is no effect or negative shift in prothrombin time. 
Haemostatic 
markers 
The 
indicator 
for normal 
pregnancy 
in III 
trimester * 
In patients 1-7 
days prior to 
administration 
of rFVIIȎ 
During 
bleeding 
After rFVIIȎ administration 
In 30 
min 
In 1–5 
hours 
In 24 
hours 
In 2-5 
days 
Platelets, 
x109/l 
146-429 166,7±5,18 
136,1± 
8,8 
65±5,9 
62,67± 
6,8 
81,5± 
9,2 
104,7± 
16,3 
PT, ratio 0,87 1,31 1,04 1,2 1,3 1,6 1,1 
APPT, ratio 0,91 1,9 1,0 0,81 0,89 1,0 1,5 
Fibrinogen, 
g/l 
3.7-6.2 3,07±0,32 2±0,09 - 
1,27± 
0,006 
3,75± 
0,55 
2,94± 
0,2 
Аntithrombin, 
% 
82 - 116 108±0,75 59±6,2 55±0,2 42±0,15 82±0,09 
91,86±2,
2 
Table 12. Hemostasis markers in patients with obstetrical DIC (subgroup 2) before and after 
rFVIIa administration (X ± m) 
Haemostatic 
markers 
Subgroup 1 Subgroup 2 
During 
bleeding 
After rFVIIa 
administration During 
bleeding 
After rFVIIa 
administration 
In 1-5 
hours 
In 24 hours 
In 1-5 
hours 
In 24 
hours 
Platelets, 
x109/l 
177,6±8,2 114±7,9 146±9,48 136,1±8,8 62,67±6,8 81,5±9,2 
PT, ratio 1,16 0,87 1,05 1,04 1,3 1,6 
Fibrinogen, g/l 2,15±0,14 2,02±0,01 2,55±0,12 2±0,09 1,27±0,006 3,75±0,55 
Аntithrombin, 
% 
86±3,5 67,67±1,8 91,38±1,59 59±6,2 42±0,15 82±0,09 
Table 13. The dynamics of main hemostatic markers in women with PPH after rFVIIa 
administration (X ± m) 
With all the results shown, as well as the fact of the massive reduction of anticoagulant 
potential (antithrombin activity) in DIC-related PPH and rFVIIa administration , a higher 
risk of developing or enhancing organ dysfunction associated with blockade of 
microcirculation can be indicated in this subgroup, which is described and mentioned in a 
number of publications devoted to the study of aseptic and septic DIC (Eisele & Lamy, 1998; 
Macphail & Talks, 2004; Schouten et al., 2008; Vinazzer, 1995). 
It is known that antithrombin acts as heparin cofactor and related to the most important 
inhibitors of blood clotting, it accounts approximately 80% of anticoagulant potential 
(LaBelle & Kitchens, 2007; Opal et al., 2002; Practical hemostasis and thrombosis, 
2005; Rublee et al., 2002). When antithrombin activity in plasma falls below 70% the risk of 
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pathological clotting progressively increases, and it is greater, the greater the anticoagulant 
deficiency. Decrease in antithrombin activity to the level of 30-50% of the physiological 
norm leads to a generalized, unrestrained thrombinemia and massive thrombosis in vessels 
of any size. In this case, antithrombin half-life shortens dramatically, and can be only a few 
hours (especially with therapeutic doses of heparin) (Vinazzer, 1995).  
Decrease in antithrombin activity in patients below 70% in different types of pathology 
requires replacement therapy to recover the physiological norm (about 80-120%) (LaBelle & 
Kitchens, 2007; Schouten et al., 2008; Schwartz et al., 1989). To cover antithrombin small 
supply, commercial products of anticoagulants or fresh frozen plasma (FFP) can be used. 
Note, however, that the massive transfusion of FFP (20-25 ml/kg) may lead to hypervolemia 
and risk of interstitial pulmonary edema, if symptoms of renal failure and the termination of 
bleeding occur. In these cases, we believe, we can use combined application of antithrombin 
preparation and FFP (dose of 7-10 ml/kg).  
We also believe that support of sustainable balance of pro- and anticoagulant systems of 
hemostasis in patients with systemic bleeding after rFVIIa administration will reduce the risk 
of thrombotic events, lessening or strengthening of potential multiple organ failure (Pic. 2). 
 
Pic. 2. Systematic hemostasis interaction in oder to balance coagulation / anticoagulation 
and fibrinolysis / antifibrinolysis, which when altered, results in haemorrage or thrombosis 
(after Buenso S.R., 2007) 
If to look back at the reactions of hemostatic system to the introduction of rFVIIa in women 
with obstetric DIC and PPH, we conclude that PT, on average data, was not shortened, but 
in most cases, lengthened or remained normal at the time of registration of bleeding. In our 
view, the lack of shortening of PT in first two hours after rFVIIa administration may serve as 
a predictor of its low hemostatic activity, as well as the little impact of repeated injections of 
rFVIIa.  
It was previously shown that the use of rFVIIa has the worst hemostatic effect in patients 
with severe coagulopathy, acidosis and hypothermia (Aggarwal et al., 2004; Bomken et al., 
2009; Dutton, 2004; Eikelboom et al., 2003; Martinowitz & Michaelson, 2005; Mayo et al., 
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2004; Mittal & Watson, 2006; O’Connell et al., 2003). It was shown in these studies that 
effective pharmacologic hemostasis with use of rFVIIa can be expected with the following 
parameters of blood:  
- prothrombin time <1.5 hours upper limit of normal;  
- Clauss fibrinogen> 1.0 g / L;  
- platelet count > 50 × 109 / L;  
- along with the above laboratory indices pH > 7.1 is also desirable for optimal effect;  
- exclusion of hypothermia.  
In the course of the research we have corrected the present parameters with the means of 
transfusion therapy, which was aimed at the recovery of hemostatic abilities in the blood, 
maintenance of the acid-base balance and the quantity of red blood cells to oxygenize 
tissues. It should be noted that in our research the volume and components of such a 
therapy were practically the same in the study and control groups. At the same time 
patients of the study group experiencing PPH and DIC (subgroup 2) received the bigger 
volume of the transfusion therapy as compared to subgroup 1 (table 14). The information we 
obtained about changes in hemostasis during haemostatic therapy allows us to estimate the 
importance of such studies in pregnant women and offer recommendations how to treat 
patients with PPH as evidenced by a number of experts (Ahonen et al., 2010; Bomken et al., 
2009; Franchini et al., 2007; Sobieszczyk & Breborowicz, 2004). 
Criteria of comparison 
Study group (n=75) 
Р value Subgroup 1 
(n=47) 
Subgroup 2 
(n=28) 
Х ± m Х ± m 
Total volume of 
transfusions, ml 
2937,2 ± 630,1 5340,8 ± 1207,0 0,05 
FFP, ml 1381,1 ± 314,9 2975,6 ± 702,7 0,01 
Red blood cells, ml 1003,2 ± 213,7 1725,4 ± 770,1 Р>0,05 
Platelets concentrates, U 0 4,13 ± 1,1 - 
Table 14. Transfusion therapy in women to study group 
Among the questions raised above we were interested in the possibility of arterial and 
venous thrombosis development during treatment with rFVIIa. In the analysis of 75 cases of 
rFVIIa treatment of women with PPH, represented by Franchini et al. (2007) there were no 
evidence of venous thrombosis. The recent work of Bomken et al. (2009) also demonstrated 
the absence of thrombosis during treatment with rFVIIa, in spite of the increasing 
thrombogenicity inherent to physiological pregnancy. In addition, several reports indicated 
a low risk of venous thromboembolism in previously healthy patients, even with the 
development of DIC (Martinowitz & Michaelson, 2005; Moscardo et al., 2001.). In general, 
the majority of thrombotic events due to the application of rFVIIa, have arterial origin and 
are determined in patients with pre-existing thrombogenic risk factors (Biss & Hanley, 
2006.). Nevertheless, as well as the number of authors, and according to materials of existing 
international recommendations (Franchini et al., 2007; Lim et al., 2004; Martinowitz & 
Michaelson, 2005; Ohkuchi et al., 2003; Vincent et al., 2006; Welsh et al., 2008; World Health 
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Organization [WHO], 2009), we recommend care in using this systemic haemostatic 
medicine in women with high risk of thromboembolism, such as cancer, including 
reproductive organs, air embolism, antiphospholipid syndrome, and thromboembolic 
syndrome present in history and in close blood relatives. In these cases it is vital to apply 
therapy or medication for thromboprophylaxis. 
6. Discussion 
In general the data that we obtained suggests that rFVIIa is a highly efficient hemostatic 
means to treat women with PPH, who are unable to respond to classical methods of 
haemostatic therapy. In accordance with the effectiveness criteria used in the present study 
women with massive local (uterine) bleeding, caused by uterine hypotony and atony in 
which the use of rFVIIa prescribed to avoid hysterectomy in most cases (80.9%) proved to 
have haemostatic effect, with no lethality among patients. Women with PPH due to the 
abruptio placentae combined with Kuveler’s uterine and placenta increta had relatively 
lower hemostatic effectiveness. On the other hand patients with obstetrical DIC (without 
organ dysfunction) and PPH the use of rFVIIa can also be justified due to health reasons, 
though relatively less effective. In cases of obstetrical DIC, massive bleeding and developing 
of organ dysfunction haemostatic effect of rFVII is extremely doubtful. 
Cases of failure of pharmacological correction of bleeding with rFVIIa can be attributed to 
resistance, for various reasons, of the blood coagulation system to activation of redundant 
quantity of factor VIIa (Franchini et al., 2007; Selo-Ojeme & Okonofua, 1997; Shander et 
al.,2005; Sobieszczyk & Breborowicz, 2004), as well as by the presence of organ dysfunction, 
which led to adverse outcome in 6 out of 11 women (54.5%) in our observations. 
It is important to note that the use of rFVIIa in massive bleeding leads to further 
consumption of platelets and fibrinogen, which is consistent with the modern explanation of 
the mechanism of its hemostatic action, but to reduce the risk of development or 
strengthening of possible multiple organ failure in obstetrical DIC it is important to recover 
the deficit not only of platelets and clotting factors, but also of physiological anticoagulants. 
The optimal tactics in the period after rFVIIa administration is 3-7 days of corrective 
replacement therapy of fresh frozen plasma (at a dose of 7-10 ml / kg) in combination with 
antithrombin preparation, to restore the activity of the latter, tentatively, to 100-120% of 
normal levels. The role of efficient and high-quality laboratory diagnostics of dynamics and 
basic parameters of coagulation (platelet count, PT, fibrinogen concentration and 
antithrombin activity) goes without questioning. 
Based on this data, we include rFVIIa in a scheme of therapy of obstetric hemorrhage, 
proposed by WHO, for the prevention of invasive and radical interventions in the treatment 
of PPH vital for haemostas management (World Health Organization [WHO], 2009) - See 
Pic. 3. 
We also believe that the use of tranexamic acid in the therapeutic tactics proves to be 
effective in cases of PPH, due to local uterine bleeding. However, the threat of emerging or 
strengthening of organ dysfunction or venous thromboembolism based on fibrinolytic 
reaction suppression seems substantial and dangerous to mother's life. 
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Pic. 3. Potential role of rFVIIa in treatment of PPH to reduce the number of radical operative 
interventions 
7. Conclusion 
We state that the resources of our own and those available publicly in regard to this issue 
received in non-controlled and nonrandomized studies, otherwise is impossible because of 
ethical reasons in obstetric practice of critical conditions (Bomken et al., 2009). Nevertheless, 
the accumulation and subsequent analysis of cases of rFVIIa administration in treating PPH 
will contribute to creating overall and clear recommendations for specialists in this field. 
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